GET IN TOUCH

MedRyge Clinical Execution Assurance™

Design it right. Execute it right. Prove it was right.

Clinical programmes need more than a sound strategy. They need to be executable, controlled, visible and capable of demonstrating appropriate sponsor oversight. MedRyge Clinical Execution Assurance™ provides an independent cross-functional framework across the study lifecycle to identify risk earlier, strengthen execution, improve decision visibility and build evidence of control.

Clinical execution assurance across the study lifecycle

Flagship USP

Clinical Execution Assurance™ is the core MedRyge differentiator: an independent view across clinical operations, quality, data, technology, vendors and commercial performance—connecting what was planned, what is actually happening, what decisions were made and whether corrective actions are working.

01

Protocol-to-Execution Readiness™

Is your protocol ready for the real world?

A scientifically compelling protocol can still be difficult to execute. We stress-test proposed study design before operational complexity becomes recruitment delay, cost escalation or quality risk.

  • Recruitment feasibility and screen-failure risk
  • Patient burden: visits, procedures, travel, ePRO and follow-up
  • Site burden: staffing, equipment, imaging, laboratory, pharmacy and documentation
  • Endpoint executability and standardisation
  • Data complexity, external data and reconciliation requirements
  • Technology and integration requirements
  • Monitoring, SDV and quality implications
  • Critical vendor dependencies and operational assumptions

Outcome: Identify execution risk before the first patient is enrolled, with a Trial Execution Readiness Score™, risk heat map, optimisation recommendations and readiness roadmap.

02

Sponsor Oversight Office™

Outsource execution. Never outsource visibility.

Sponsors may outsource substantial portions of a programme, but they still need independent understanding of whether the programme is under control. MedRyge provides a consolidated sponsor-side view across functions and vendors.

  • Study milestones, recruitment, activation and monitoring
  • CRO performance, resources, turnaround times and deliverable quality
  • Site performance, data entry, queries, deviations and document status
  • Clinical data, coding, reconciliation and external data
  • TMF completeness, timeliness and ageing
  • Safety workflows and reconciliation
  • Quality events, CAPAs and recurring findings
  • Vendor performance, dependencies and open issues
  • Budget, change orders, pass-throughs and cost-to-complete

Outcome: Independent programme visibility through an executive oversight dashboard, CRO assessment, escalation register, governance support and decision/action tracking.

03

Clinical Trial Health & Rescue™

Know why the study is struggling before trying to fix it.

Study underperformance is often cross-functional. Rather than treating symptoms in isolation, MedRyge diagnoses the underlying drivers across recruitment, sites, monitoring, data, quality, governance, vendors and cost.

  • Recruitment versus plan, screen failure and recruitment forecasts
  • Site activation, investigator engagement and inactive-site analysis
  • Monitoring backlog, follow-up actions and critical findings
  • Data-entry timeliness, queries, coding and cleaning status
  • Protocol deviations, eligibility errors and missing assessments
  • Safety and TMF performance
  • Vendor delays and cross-functional dependencies
  • Governance, escalation and decision-making effectiveness
  • Burn rate, forecast, change orders and cost-to-complete

Outcome: Diagnose first and recover intelligently using a Study Health Score™, Root Cause Map, critical risk map, 30/60/90-day recovery plan and executive recovery dashboard.

04

Clinical Vendor Commercial Assurance™

Know what you are paying for—and why.

CRO and specialist-vendor proposals can appear comparable while relying on materially different assumptions, units, resource models and pass-through structures. MedRyge combines clinical operational understanding with commercial review.

  • CRO budget normalisation for side-by-side comparison
  • Scope and assumption matrix
  • Resource, monitoring, PM and start-up assumptions
  • Technology and data-management fees
  • Travel, pass-throughs and vendor-management fees
  • Bid-defence challenge and negotiation support
  • Change-order reasonableness and scope assessment
  • Invoice reconciliation, budget-to-actual review and forecasting
  • Budget leakage analysis and cost-to-complete

Outcome: Improve commercial visibility before selection and throughout execution, reducing avoidable ambiguity, leakage and unsupported change.

05

ICH E6(R3) Readiness 360™

Move from understanding E6(R3) to operating under it.

Guideline awareness is not the same as operational readiness. We assess how E6(R3) principles translate into study design, risk management, sponsor oversight, data governance, clinical systems, procedures and training.

  • Quality by Design and critical-to-quality factors
  • Risk-Based Quality Management
  • Sponsor oversight and vendor governance
  • Proportionate monitoring strategy
  • Data governance and data-flow control
  • Computerised systems and digital/decentralised trial elements
  • SOP and process impact
  • Role-based training and implementation needs

Outcome: Turn regulatory change into operational readiness through a gap assessment, Readiness Index™, critical-gap register, SOP impact analysis and implementation roadmap.

06

Inspection Evidence Readiness™

Can you demonstrate that your trial was under control?

Inspection readiness is more than document completeness. We focus on the evidence chain connecting risk, signals, oversight, decisions, actions, closure and effectiveness.

  • Sponsor oversight and CRO governance
  • Monitoring, TMF, clinical data and safety
  • Vendor performance and quality events
  • CAPAs and risk management
  • Clinical systems and decision documentation
  • Escalations and follow-through
  • Evidence linking governance decisions to study execution
  • Mock evidence requests and interview preparation

Outcome: Do not just be inspection-ready; be able to demonstrate control through an Inspection Evidence Map™, oversight evidence register, missing-evidence assessment and remediation priorities.

07

Digital Clinical Assurance™

Is your clinical technology fit for the work you expect it to do?

Clinical organisations increasingly depend on SaaS, cloud platforms, eClinical systems, AI and specialist technology providers. We evaluate whether systems are appropriately selected, validated, governed, integrated and used for their intended clinical purpose.

  • Intended use and clinical-process criticality
  • System risk to participant safety, data reliability and study decisions
  • Technology-vendor governance
  • Risk-based validation strategy
  • Data integrity, audit trails and access management
  • Integrations across EDC, CTMS, eTMF, IWRS, ePRO, safety, labs and analytics
  • System upgrades, configuration changes and lifecycle control
  • AI intended use, human oversight, output review, traceability, model/change governance and escalation

Outcome: Enable digital innovation with clinical control through technology risk assessment, digital maturity scoring, validation strategy, integration risk mapping and AI governance.

08

Virtual Sponsor Office™

Build the clinical programme before you build the entire organisation.

Emerging biotechnology organisations may have strong science but limited clinical-development infrastructure. MedRyge can provide flexible sponsor-side capability without replacing the CRO or the sponsor’s strategic ownership.

  • Clinical programme and study strategy
  • CRO selection and oversight
  • Vendor governance and clinical operations
  • Clinical quality and data oversight
  • Clinical technology strategy
  • Programme risk management and study dashboards
  • Executive reporting and cross-functional coordination
  • Study-health assessment and development milestone tracking

Outcome: Sponsor-side capability and structure for virtual biotech, early-stage biopharma, first-in-human programmes and lean clinical-development teams.

Start a conversation
Also Lab to Market Advisory Next Specialist Advisory